Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, six-sequence crossover study evaluating the relative oral abuse potential of NKTR-181 compared to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of opioids who can identify drug effects that are relevant to abuse risk assessment

Trial Profile

A randomized, double-blind, placebo-controlled, six-sequence crossover study evaluating the relative oral abuse potential of NKTR-181 compared to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of opioids who can identify drug effects that are relevant to abuse risk assessment

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs NKTR 181 (Primary) ; Oxycodone
  • Indications Back pain; Musculoskeletal pain; Pain
  • Focus Pharmacokinetics; Registrational
  • Acronyms HAP
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 30 Jul 2018 According to a Nektar Therapeutics media release, the U.S. FDA has filed and accepted for review of the companys NDA for NKTR-181 for the treatment of chronic low back pain in adult patients new to opioid therapy. The NDA is expected to be assigned a PDUFA (Prescription Drug User Fee Act) target action date of 28 May 2019 by the FDA.
    • 31 May 2018 According to a Nektar Therapeutics media release, the company has submitted a NDA to the US FDA for NKTR-181, a first-in-class investigational opioid to treat chronic low back pain in adult patients new to opioid therapy, based on the data of: Efficacy study (243040); a long-term 52-week safety study (254129); pharmacokinetic/pharmacodynamic studies in over 450 subjects; and two human abuse potential studies of NKTR-181 versus an oxycodone control in recreational drug users (220652 and 282808)
    • 10 May 2018 According to an Nektar Therapeutics media release, data will be presented at the American Society for Clinical Oncology (ASCO) 2018 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top